Sangamo Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Sangamo Therapeutics reported Q4 2025 earnings on March 30, 2026, missing analyst expectations with a loss per share of $0.07, $0.03 worse than projected. Revenue reached $14.23 million, an 88.43% year-over-year increase but fell $26.02 million short of estimates, signaling ongoing financial challenges despite growth. The earnings call slide deck was released alongside the results, providing investors with detailed operational and financial updates for the quarter. The company continues to focus on gene therapy and genome editing, though the earnings shortfall raises questions about its near-term commercial viability. Seeking Alpha’s transcripts team published the earnings call details, expanding coverage of biotech financial disclosures for investor analysis.